Safety analysis of statins

This article examines the efficacy and safety of statins. It examines the main reasons for failure to achieve target lipid levels. The causes of adverse reactions to these medications, their incidence, and possible mechanisms for the development of statin-associated muscle symptoms are analyzed. The article discusses drug interactions between statins and other medications, particularly the coadministration of statins and P2Y12 platelet receptor inhibitors, primarily ticagrelor.

1. Gencer B., Marston N. A., Im K. et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637–43. https://doi.org/10.1016/S0140-6736(20)32332-1.

2. Silverman M. G., Ference B. A., Im K. et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297.

3. Virani S. S., Ramsey D. J., Westerman D. et al. Cluster randomized trial of a personalized clinical decision support intervention to improve statin prescribing in patients with atherosclerotic cardiovascular disease. Circulation. 2023;147(18):1411–1413.

4. Shahbaz S. K., Sadeghi M., Koushki K. et al. Regulatory T cells: possible mediators for the anti-inflammatory action of statins. Pharmacologicalresearch. 2019;149:104469.

5. Taqueti V. R., Ridker P. M. Lipid-lowering and anti-inflammatory benefits of statin therapy: more than meets the plaque. Circulation: Cardiovascular Imaging. 2017;10(7):e006676.

6. Liu C., Shen M., Tan W. L. W. et al. Statins improve endothelial function via suppression of epigenetic-driven EndMT. Nature cardiovascular research. 2023;2(5):467–485. https://doi.org/10.1038/s44161-023-00267-1.

7. Bakakos A., Oikonomou E., Vogiatzi G. et al. Statins and left ventricular function. Current Pharmaceutical Design. 2017;23(46):7128–7134. https://doi.org/10.2174/1381612823666170926125754.

8. Phillip Owens III A., Mackman N. The antithrombotic effects of statins. Annual review of medicine. 2014;65(1):433–445. https://doi.org/10.1146/annurev-med-051812-145304.

9. Zeng W., Denga H., Luoa Y. et al. Advances in statin adverse reactions and the potential mechanisms: A systematic review. Journal of Advanced Research. 2025;76:781–797. https://doi.org/10.1016/j.jare.2024.12.020.

10. Karpov Yu.A. The role of statin therapy in the prevention of cardiovascular disease in real-world clinical practice. Doctor.Ru. 2021; 20(11): 17–27. (In Russ.). https://doi.org/10.31550/1727-2378-2021-20-11-17-27.

11. Nanna M. G., Navar A. M., Wang T. Y. et al. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018;7:e008546. https://doi.org/10.1161/JAHA.118.008546.

12. Vinci P., Panizon E., Tosoni L. M. et al. Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. Int. J. Mol. Sci. 2021;22:11687. https://doi.org/10.3390/ijms222111687.

13. Pogosova N. V., Boytsov S. A. Preventive cardiology in 2024: current state of the art and development prospects. Cardiology. 2024;64(1):413. (In Russ.). https://doi.org/10.18087/cardio.2024.1.n2636.

14. Ezhov M. V., Kukharchuk V. V., Sergienko I. V. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5471.

15. Rosenson R. S., Baker S. K. Jacobson T. A. et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71. https://doi.org/10.1016/j.jacl.2014.03.004.

16. Jacobson T. A., Edelman S. V., Galipeau N. et al. Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient. 2016;10(3):321–334. https://doi.org/10.1007/s40271-016-0211-y.

17. Stroes E. S., Thompson P. D., Corsini A. et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015;36:1012–1022. https://doi.org/10.1093/eurheartj/ehv043.

18. Mach F., Koskinas K. C., Roeters van Lennep J. E. et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of Информация об авторахdyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Free. European Heart Journal. 2025;46(Issue 42):4359–4378. https://doi.org/10.1093/eurheartj/ehaf190.

19. Averkov O. V., Harutyunyan G. K., Duplyakov D. V. et al. 2024 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation electrocardiogram. Russian Journal of Cardiology. 2025;30(5):6319. (In Russ.). https://doi.org/10.15829/1560-4071-2025-6319. EDN: CXJUIB.

20. Rao S. V., O’Donoghue M. L., Ruel M. et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135–2237. https://doi.org/10.1016/j.jacc.2024.11.009.

21. Sahoo A. K., Singh A., Gupta D. et al. Assessment of potential drugdrug Interactions (pDDIs) and their risk factors among hospitalized cardiac patients in a tertiary-care center of Central India: a retrospective record-based study. Hosp Pharm. 2024;59(1):24–31. https://doi.org/10.1177/00185787231182569.

22. Roule V., Alexandre J., Lemaitre A. et al. Rhabdomyolysis with coadministration of statins and antiplatelet therapies-analysis of the WHO pharmacovigilance database. Cardiovasc Drugs Ther. 2023;38(6):1191-1199. https://doi.org/10.1007/s10557-023-07459-8.

23. Patel R., Sharma J. B., Rajput S. Statins ticagrelor and rhabdomyolysis: a coincidence or a drug interaction? J Lipid Atheroscler. 2024;13(1):618. https://doi.org/10.12997/jla.2024.13.1.61.

24. Lehtisalo M., Tarkiainen E. K., Neuvonen M. et al. Ticagrelor increases exposure to the breast cancer resistance protein substrate rosuvastatin. Clin Pharmacol Ther. 2024;115(1):71–9. https://doi.org/10.1002/cpt.3067.

25. Rajput M., Rizvi S., Pratap P. D. et al. Pharmacokinetics and lipidlowering efficacy affected by polymorphisms in genetic variability in statin therapy. Egyptian Journal of Medical Human Genetics. 2025;26:160. https://doi.org/10.1186/s43042-025-00787-4.

26. Rocca B., Bigagli E., Cerba E. Ticagrelor and Statins: Dangerous Liaisons? Cardiovascular Drugs and Therapy. 2024;38:1103–1109. https://doi.org/10.1007/s10557-024-07624-7.

27. Masolitin S. V., Protsenko D. N., Tyurin I. N. et al. A modern approach to the use of extracorporeal detoxification methods for rhabdomyolysis (review). General Resuscitation. 2022;18(3):59–68. (In Russ.). https://doi.org/10.15360/1813-9779-2022-3-59-68.